Agents with a dominant or highly significant serotonergic pathway(s) modulating mechanism of action
Buspirone HCl is a classic 5-HT1A partial agonist with relatively high affinity (Ki = 9.3 - 29.5 nM). A clinically effective anxiolytic. Research Indications: Anxiolytic Research, Addiction Cessation (incl. Smoking/Nicotine) Research, Autism Research, Serotonergic Research
Ketanserin Tartrate is a potent and selective 5HT2A antagonist. It has demonstrated neurogenic, addiction cessation, sleep enhancement, anxiolytic, and anti=psychotic properties, among others Research Indications: Serotonergic research, Anxiolytic Research, Psychoneurodysfunctional Research, HPPD-related Research.
Dapoxetine is the first compound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old. Dapoxetine works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. Research Indications: Libidogenic/Sex Research, Serotonergic...
Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist. Flibanserin has high affinity for human 5-HT1A receptors (Ki = 1 nm) and lower affinity for 5-HT2A (Ki = 49 nm) and D4 (Ki = 4–24 nm) receptors. Research Indications: Libidogenic/Sex Research, Antidepressant Research, Anxiolytic Research, Serotonergic Research
Tianeptine is a full agonist at the at the μ and δ opioid receptors with negligible effect at the κ opioid receptors. Research suggests that tianeptine produces its antidepressant effects through indirect alteration of glutamate receptor activity (i.e.,AMPA receptors and NMDA receptors) and release of BDNF, in turn affecting neural plasticity.
Prucalopride is a first in class dihydro-benzofuran-carboxamide that displays high potency, high selectivity, and high affinity as a 5HT4 full agonist. Agents of this class demonstrate rapid-acting, potent antidepressant, neurogenic, and nootropic properties. Research Indications: Antidepressant Research, Neurogenic Research, Nootropic Research